Vaccines and other immunological approaches for cancer immunoprevention

Pier Luigi Lollini, Giordano Nicoletti, Lorena Landuzzi, Federica Cavallo, Guido Forni, Carla de Giovanni, Patrizia Nanni

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The immune system effectively prevents cancer, whereas severe immunodepression increases its incidence. Cancer immunoprevention is a strategy based on the concept that enhancement of tumor immunity in healthy individuals reduces cancer risk. It can be viewed as a kind of chemoprevention. For cancer immunoprevention, the cancer universe can be neatly divided between tumors caused - directly or indirectly - by infectious agents and all other tumors. Immunoprevention of tumors caused by infectious agents is already implemented at the population level for hepatitis B virus (HBV)-related hepatocellular carcinoma and for tumors caused by human papillomaviruses (HPV), like cervical carcinoma. Now the challenge is to develop immunological strategies to prevent the bulk (>80%) of human tumor burden, unrelated to infections. Both vaccines against tumor antigens and immune modulators can prevent tumor onset in cancerprone mice. These studies outlined the target antigens and the molecular and cellular mechanisms of cancer immunoprevention: a) the best target antigens are surface molecules controlling tumor growth and progression (oncoantigens); b) combinations of potent vaccines and nonspecific stimuli (adjuvants) yield the strongest protection; c) immunoprevention must start early in the natural history of tumors, before key progression events like the onset of carcinoma in situ; d) lifetime protection requires repeated boosts, to maintain a strong and steady immune response; e) antibodies and helper, rather than cytotoxic, T cells mediate long-term protection from tumor onset; f) immunoprevention can be combined with chemoprevention. The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans.

Original languageEnglish
Pages (from-to)1957-1973
Number of pages17
JournalCurrent Drug Targets
Volume12
Issue number13
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Tumors
Vaccines
Neoplasms
Chemoprevention
Combined Vaccines
T-cells
Immune system
Neoplasm Antigens
Tamoxifen
Surface Antigens
Viruses
Modulators
Carcinoma in Situ
Antigens
Molecules
Tumor Burden
Antibodies
Hepatitis B virus
Immunosuppression
Hepatocellular Carcinoma

Keywords

  • Antibodies
  • Cancer vaccines
  • ErbB2
  • Immunoprevention
  • Mammary carcinoma
  • Oncoantigens
  • Viral tumors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Vaccines and other immunological approaches for cancer immunoprevention. / Lollini, Pier Luigi; Nicoletti, Giordano; Landuzzi, Lorena; Cavallo, Federica; Forni, Guido; de Giovanni, Carla; Nanni, Patrizia.

In: Current Drug Targets, Vol. 12, No. 13, 12.2011, p. 1957-1973.

Research output: Contribution to journalArticle

Lollini, Pier Luigi ; Nicoletti, Giordano ; Landuzzi, Lorena ; Cavallo, Federica ; Forni, Guido ; de Giovanni, Carla ; Nanni, Patrizia. / Vaccines and other immunological approaches for cancer immunoprevention. In: Current Drug Targets. 2011 ; Vol. 12, No. 13. pp. 1957-1973.
@article{156924a736fe4100bada02b208abcd91,
title = "Vaccines and other immunological approaches for cancer immunoprevention",
abstract = "The immune system effectively prevents cancer, whereas severe immunodepression increases its incidence. Cancer immunoprevention is a strategy based on the concept that enhancement of tumor immunity in healthy individuals reduces cancer risk. It can be viewed as a kind of chemoprevention. For cancer immunoprevention, the cancer universe can be neatly divided between tumors caused - directly or indirectly - by infectious agents and all other tumors. Immunoprevention of tumors caused by infectious agents is already implemented at the population level for hepatitis B virus (HBV)-related hepatocellular carcinoma and for tumors caused by human papillomaviruses (HPV), like cervical carcinoma. Now the challenge is to develop immunological strategies to prevent the bulk (>80{\%}) of human tumor burden, unrelated to infections. Both vaccines against tumor antigens and immune modulators can prevent tumor onset in cancerprone mice. These studies outlined the target antigens and the molecular and cellular mechanisms of cancer immunoprevention: a) the best target antigens are surface molecules controlling tumor growth and progression (oncoantigens); b) combinations of potent vaccines and nonspecific stimuli (adjuvants) yield the strongest protection; c) immunoprevention must start early in the natural history of tumors, before key progression events like the onset of carcinoma in situ; d) lifetime protection requires repeated boosts, to maintain a strong and steady immune response; e) antibodies and helper, rather than cytotoxic, T cells mediate long-term protection from tumor onset; f) immunoprevention can be combined with chemoprevention. The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans.",
keywords = "Antibodies, Cancer vaccines, ErbB2, Immunoprevention, Mammary carcinoma, Oncoantigens, Viral tumors",
author = "Lollini, {Pier Luigi} and Giordano Nicoletti and Lorena Landuzzi and Federica Cavallo and Guido Forni and {de Giovanni}, Carla and Patrizia Nanni",
year = "2011",
month = "12",
doi = "10.2174/138945011798184146",
language = "English",
volume = "12",
pages = "1957--1973",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Vaccines and other immunological approaches for cancer immunoprevention

AU - Lollini, Pier Luigi

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - Cavallo, Federica

AU - Forni, Guido

AU - de Giovanni, Carla

AU - Nanni, Patrizia

PY - 2011/12

Y1 - 2011/12

N2 - The immune system effectively prevents cancer, whereas severe immunodepression increases its incidence. Cancer immunoprevention is a strategy based on the concept that enhancement of tumor immunity in healthy individuals reduces cancer risk. It can be viewed as a kind of chemoprevention. For cancer immunoprevention, the cancer universe can be neatly divided between tumors caused - directly or indirectly - by infectious agents and all other tumors. Immunoprevention of tumors caused by infectious agents is already implemented at the population level for hepatitis B virus (HBV)-related hepatocellular carcinoma and for tumors caused by human papillomaviruses (HPV), like cervical carcinoma. Now the challenge is to develop immunological strategies to prevent the bulk (>80%) of human tumor burden, unrelated to infections. Both vaccines against tumor antigens and immune modulators can prevent tumor onset in cancerprone mice. These studies outlined the target antigens and the molecular and cellular mechanisms of cancer immunoprevention: a) the best target antigens are surface molecules controlling tumor growth and progression (oncoantigens); b) combinations of potent vaccines and nonspecific stimuli (adjuvants) yield the strongest protection; c) immunoprevention must start early in the natural history of tumors, before key progression events like the onset of carcinoma in situ; d) lifetime protection requires repeated boosts, to maintain a strong and steady immune response; e) antibodies and helper, rather than cytotoxic, T cells mediate long-term protection from tumor onset; f) immunoprevention can be combined with chemoprevention. The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans.

AB - The immune system effectively prevents cancer, whereas severe immunodepression increases its incidence. Cancer immunoprevention is a strategy based on the concept that enhancement of tumor immunity in healthy individuals reduces cancer risk. It can be viewed as a kind of chemoprevention. For cancer immunoprevention, the cancer universe can be neatly divided between tumors caused - directly or indirectly - by infectious agents and all other tumors. Immunoprevention of tumors caused by infectious agents is already implemented at the population level for hepatitis B virus (HBV)-related hepatocellular carcinoma and for tumors caused by human papillomaviruses (HPV), like cervical carcinoma. Now the challenge is to develop immunological strategies to prevent the bulk (>80%) of human tumor burden, unrelated to infections. Both vaccines against tumor antigens and immune modulators can prevent tumor onset in cancerprone mice. These studies outlined the target antigens and the molecular and cellular mechanisms of cancer immunoprevention: a) the best target antigens are surface molecules controlling tumor growth and progression (oncoantigens); b) combinations of potent vaccines and nonspecific stimuli (adjuvants) yield the strongest protection; c) immunoprevention must start early in the natural history of tumors, before key progression events like the onset of carcinoma in situ; d) lifetime protection requires repeated boosts, to maintain a strong and steady immune response; e) antibodies and helper, rather than cytotoxic, T cells mediate long-term protection from tumor onset; f) immunoprevention can be combined with chemoprevention. The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans.

KW - Antibodies

KW - Cancer vaccines

KW - ErbB2

KW - Immunoprevention

KW - Mammary carcinoma

KW - Oncoantigens

KW - Viral tumors

UR - http://www.scopus.com/inward/record.url?scp=79953835805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953835805&partnerID=8YFLogxK

U2 - 10.2174/138945011798184146

DO - 10.2174/138945011798184146

M3 - Article

VL - 12

SP - 1957

EP - 1973

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -